Roth Capital Downgrades Alpharma (ALO) to Hold
More News related to ALO
- Alstom Announces Appointment of North American Executives
- Top 15 For 2008 (No. 14): M&A Wreckage
- King Pharmaceuticals (KG) Completes Acquisition of Alpharma
- King Completes Acquisition of Alpharma
- Standard & Poor's Announces Changes to U.S. Indices
More News related to KG
- Top 15 For 2008 (No. 14): M&A Wreckage
- Acura Pharma (ACUR) Submits NDA for Acurox(r) Tablets
- New Drug Application Submitted For Acurox(r) Tablets
- King Pharmaceuticals (KG) Updates FDA Review of NDA for EMBEDA
- King Pharmaceuticals Provides Update on EMBEDA(TM) NDA Review
More News related to Downgrades
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
Roth Capital downgrades Alpharma, Inc. (NYSE: ALO) from Buy to Hold with a $36 price target.
On Friday, Alpharma received an unsolicited $33/share offer from King Pharmaceuticals, Inc. (NYSE: KG), which the company determined to be not in the best interests of shareholders.
Related Categories
DowngradesStocks Mentioned
+0.00
-0.32Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
